Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse

Pulmonary Pharmacology and Therapeutics

Volumn 27, Issue 2, 2014, Pages 170-178

  Riffo Vasquez, Yanira ^a   Man, Francis ^a   Page, Clive P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Doxofylline; Inflammation; LPS; Lung; Mice; Neutrophils

Indexed keywords

DOXOFYLLINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; THEOPHYLLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; CREMASTER MUSCLE; CYTOKINE RELEASE; DRUG MECHANISM; ESCHERICHIA COLI; IN VITRO STUDY; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LUNG LAVAGE; MALE; MICROSCOPY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; TRACHEA; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; LEUKOCYTE; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; PNEUMONIA; THEOPHYLLINE;

EID: 84895929364     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.01.001     Document Type: Article

References (19)

1. Page C.P., Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012, 12:275-286.
2. Sullivan P., Bekir S., Jaffar Z., Page C., Jeffery P., Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994, 343:1006-1008.
3. Page C.P. Doxofylline: a "novofylline". Pulm Pharmacol Ther 2010, 23:231-234.
4. van Mastbergen J., Jolas T., Allegra L., Page C.P. The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. Pulm Pharmacol Ther 2012, 25:55-61.
5. Persson C.G.A., Pauwels R. Pharmacology of anti-asthma xanthines. Pharmacology of asthma: Handbook of experimental Pharmacology 1991, vol. 98:207-221.
6. Ford P.A., Durham A.L., Russell R.E., Gordon F., Adcock I.M., Barnes P.J. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010, 137:1338-1344.
7. Franzone J.S., Cirillo R., Biffignandi P. Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF. Eur J Pharmacol 1989, 165:269-277.
8. Cogo R., Castronuovo A. Effects of oral doxofylline on inflammatory changes and altered cell proliferation in chronic obstructive bronchitis. Eur Rev Med Pharmacol Sci 2000, 4:15-20.
9. Wenzel S.E. Asthma: defining of the persistent adult phenotypes. Lancet 2006, 368:804-813.
10. Jeffery P.K. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000, 117:251S-260S.
11. Calverley P.M., Rabe K.F., Goehring U.M., Kristiansen S., Fabbri L.M., Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
12. Kornerup K.N., Salmon G.P., Pitchford S.C., Liu W.L., Page C.P. Circulating platelet-neutrophil complexes are important for subsequent neutrophil activation and migration. JAppl Phys 2010, 109:758-767.
13. Aul R., Armstrong J., Duvoix A., Lomas D., Hayes B., Miller B.E., et al. Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. Br J Clin Pharmacol 2012, 74:1023-1032.
14. Aul R., Patel S., Summerhill S., Kilty I., Plumb J., Singh D. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. Int Immunopharmacol 2012, 13:225-231.
15. Johnson Z., Kosco-Vilbois M.H., Herren S., Cirillo R., Muzio V., Zaratin P., et al. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. JImmunol 2004, 173:5776-5785.
16. Okubo Y., Hossain M., Horie S., Momose T., Suzuki J., Isobe M., et al. Inhibitory effects of theophylline and procaterol on eosinophil function. Intern Med 1997, 36:276-282.
17. Spoelstra F.M., Berends C., Dijkhuizen B., de Monchy J.G., Kauffman H.F. Effect of theophylline on CD11b and L-selectin expression and density of eosinophils and neutrophils invitro. Eur Respir J 1998, 12:585-591.
18. Momose T., Okubo Y., Horie S., Suzuki J., Isobe M., Sekiguchi M. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression. Int Arch Allergy Immunol 1998, 117:138-145.
19. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol 2008, 28:223-232.